This white paper presents the first systematic genomic profiling of Nigerian cancers, analyzing 442 variants across 41 genes. The findings reveal both global drivers (PIK3CA, KRAS, TMPRSS2 ERG) and distinctive enrichments (ALK, FGFR4), with nearly 80% of variants classified as clinically significant. The report outlines therapeutic opportunities, policy recommendations, and a roadmap for integrating precision oncology into Nigeria’s healthcare system.

Highlights:
442 variants analyzed across 50 tumors
ALK and FGFR4 mutations enriched in Nigerian cancers
80% of variants clinically significant
Policy roadmap for genomic medicine in Nigeria